I am interested in how changes in competition affect strategic firm behavior, especially non-price strategic behavior. I am also interested in how changes in information affect consumer decisions across different regulatory environments. Much of my research focuses on competition in healthcare markets, and notably physician and prescription drug markets.
My casework at the FTC also focuses on healthcare markets, and especially physician and prescription drug markets. I have investigated mergers and other potentially anticompetitive conduct (e.g., "pay-for-delay") among Pharmacy Benefit Managers (PBMs), pharmacies, generic drug firms, brand drug firms, and specialty drugs (i.e., gene therapy, medical devices, and cancer therapies). I have also investigated mergers of hospitals, consumer products, and retailers (e.g., grocery stores).
I have served as an expert handler for both internal and external experts. Some of my matters have been litigated in Federal Court. I have also been involved in transactions involving settlements worth over $1 billion. In addition, I helped draft an FTC report on authorized generic drugs that has been cited in reports to the President and proposed legislation.
In my time at the FTC, I have won several awards including the Award for Outstanding Scholarship (2021), the Francis Scott Walker Award ("FTC Economist of the Year" 2018) and the Paul Rand Dixon Award (2014), which is given to staff that contributed outstanding work to a case.
Thomas G Koch, Brett W Wendling, Nathan E Wilson
The Review of Economics and Statistics, 2020, pp. 1--38
Francine Lafontaine, Christopher J. Metcalf, David R. Schmidt, Brett W. Wendling
The Antitrust Revolution, 7th edition, 2018
Thomas Koch, Brett Wendling, Nathan E Wilson
Health services research, vol. 53, Wiley Online Library, 2018, pp. 3549--3568
Economist, Federal Trade Commission